133 results about "Liposomal Injection" patented technology

The invention discloses a xiluomosi liposome freeze dried and making technique, which comprises the following steps: selecting liposome component, buffer, organic solvent, antioxidant and freeze-drying protective as raw material; adopting film diffusion method to make the liposome turbid liquor with xiluomosi through high-pressure or hypersonic dispersing method evenly; drying the liposome to improve the storage stability obviously; dispersing the freeze dried at random proportion in the water evenly without any sediment and impurity; making the packing rate of liposome at 96% with the grain size at 50-250nm; improving the drug effect greatly in comparison with oral agent; lengthening the circulating time in the blood; elevating the biological utility of drug.

The invention discloses hydrochloric acid Fasudil liposome injection and new application thereof. The injection mainly comprises the following components according to parts by weight: 1 part of hydrochloric acid Fasudil, 2 to 20 parts of phospholipid, 0.5 to 10 parts of cholesterol and 1 to 8 parts of polysorbate 80. Simultaneously, the hydrochloric acid Fasudil liposome injection also can be used for treating vertebral artery type cervical spondylosis.

The invention discloses an anthracycline liposome injection, including the injection and a frozen powder injection and a preparation process of the injection. The frozen liposome consists of the anthracycline or an anthracycline hydrochloride, compound neutral phospholipids, surfactant, negative-charge phospholipids, buffers, PH regulators and freezing protection agent. The preparation process includes the following steps: preparation of a hollow liposome, a homogenized liposome, an anthracycline lopsome and an anthracycline lopsome suspension; adding the freezing protection agent; constant volume; sterilization; sub-package; freezing and drying; storage, etc. The liposome injection can be preserved for 12 months under the room temperature with better stability. And the encapsulation rate can be above 95 percent and a granule diameter is between 30 and 300mm. The side effect is low and the technique is simple, thus being convenient for industrial production.

The invention discloses an Argatroban liposome injection and a preparation method thereof. The Argatroban liposome injection with excellent quality is prepared by selecting Argatroban, sphingomyelin, octadecylamine, and tween 80 according to specific proportion. Compared with preparations in the prior art, the injection disclosed herein has improved stability and bioavailability, improved qualityof the preparation products, reduced toxic and side effect, stable drug release, and remarkable curative effect.

The invention provides liposome injection of an amoxicillin sodium sulbactam sodium medicinal composition. The liposome injection consists of amoxicillin sodium, sulbactam sodium, liposome carriers, freeze-drying supporting agents and optional antioxidant, wherein the liposome carriers are dipalmitoyl phosphatidyl choline and deoxysodium cholate. The liposome injection has high stability; in the freeze-drying process, a phenomenon of breaking liposome caused by dehydration, fusion, ice crystal generation and the like does not occur; and the liposome can remain good encapsulation ratio after being hydrated and redissolved.

The invention discloses levocarnitine liposomes injection, which is characterized by comprising the following active ingredients in parts by weight: 1 part of levocarnitine, 3-15 parts of soybean lecithin, 0.4-7.5 parts of cholesterol and 0.02-1 part of antioxidant, and a pharmaceutically acceptable carrier, wherein, the antioxidant is one or more of L-cysteine, thiourea, vitamin E and butylated hydroxyanisole and is most preferably the vitamin E. The invention also discloses a preferable preparation method of the levocarnitine liposomes injection, namely ammonium sulphate pH gradient method.The invention provides levocarnitine liposomes injection which has excellent stability, high entrapment rate and low leakage rate in the process of long-term storage. The acute toxicity tests, unusualtoxicity tests and heat source tests adopting the levocarnitine liposomes injection all conform to the specifications and are applicable to industrialized production.

The invention discloses pemetrexed disodium liposome injection which is mainly made of pemetrexed disodium and a preparation method thereof, distearoyl phosphatidyl glycerol, dipalmitoyl phosphatidyl choline, PEG600, cholesterol and mannitol. The liposome injection has the advantages that the particle size of liposome is small, the liposome is uniformly distributed, the encapsulation efficiency is high, the leakage rate is low, the stability is good, the solubility of the pemetrexed disodium and the quality of injection products are improved, the toxic and side effect is reduced, and the curative effect is improved.

The invention provides a liposome injection of a pharmaceutical composition of amoxicillin sodium and clavulanate potassium, which consists of amoxicillin sodium, clavulanate potassium, a liposome carrier, a lyoprotectant and a freely optional antioxidant, wherein the liposome carrier is egg yolk phosphatidylinositol and sodium taurocholate. The liposome injection has good preparation stability, liposome can avoid the fracture due to dehydration, fusion, ice crystal generation and the like during the freeze-drying process, and the liposome can still keep the good encapsulation rate after hydration and redissolution.

The invention provides icaritin liposome and a preparation method thereof. The lcaritin liposome mainly contains the following raw materials according to mass ratio: 0.01-5% of icaritin, 0.05-88% of phospholipid, 0-8% of plastification materials, 0-20% of propping agent and the balance of injection water. The preparation method comprises the following steps: completely dissolving the icaritin and the phospholipid in a organic solvent, then adopting a rotating film evaporation method for volatilizing the organic solvent completely; adding the injection water, continuously rotating a film under the normal pressure until the film is hydrated completely; emulsifying the mixture so as to obtain colostrum, conducting ultrasonic and homogenate on the colostrum, and then adopting the injection water for constant volume; and adjusting the PH value to be 4-8, then obtaining injecta preparation of the icaritin liposome, and further conducting vacuum cooling and drying on the icaritin liposome, then obtaining icaritin liposome powder preparation. Due to the icaritin liposome preparation, the icaritin treatment has better liver target property, and the stability and the bioavailability of a medicine are improved.

The invention discloses a dexamethasone palmitate acid liposome injection and a preparation method thereof. The liposome injection is prepared from dexamethasone palmitate, dispermaceti phospholipids, cholesterol, tween80, glucose and dextran according to a certain weight ratio. The liposome injection provided by the invention has good preparation stability. During a freezing process, rupture of liposome due to fusion and ice crystals are prevented. After long-term storage, good entrapment rate is maintained in the liposome. With the injection and the method provided by the invention, dissolubility of dexamethasone palmitate is improved, quality of the preparation product is improved, toxic and side-effects are reduced, retention time of the medicine in systemic circulation is prolonged, bioavailability of the medicine is improved, and the curative effect is improved. The preparation method is simple, and the method is suitable for industrial productions.

The invention relates to a lipidosome injection with dexamethasone sodium phosphate as an active component, which comprises dexamethasone sodium phosphate lipidosomes and one or more medical auxiliary materials for injection, wherein the liposome encapsulation rate of the active component is 40-70 percent, and the lipidosome injection comprises 0.025-0.5 percent of the dexamethasone sodium phosphate as the active component, 0.125-5 percent of phospholipid, 0.002-1 percent of lipophilic additive, a pH buffering agent with the pH value kept at 7-7.5 and the balance of water for injection.

The invention provides cabazitaxel long-circulation liposome injection and a preparation method thereof. The cabazitaxel long-circulation liposome injection comprises cabazitaxel or a pharmaceutically acceptable salt thereof, tocopherol polyethylene glycol succinate, distearoyl-phosphatidylethanolamine-polyethylene glycol-maleimide and phospholipid. The cabazitaxel long-circulation liposome injection is prepared by a film method. The liposome not only has the advantages of reduced toxicity, simple and convenient clinical use and improved bioavailability, but also has good stability of storage and use.

The precursor liposome powder for injection preparation has Carmustine in 3-12 wt% as main material and other components including phospholipid 19-25 wt%, sterol 3.5-6.5 wt% and support agent 54-73 wt%. Carmustine, phospholipid and sterol are compounded into solution; the solution is added into the support agent powder gradually and the mixture is vacuum dried to form Carmustine powder for injection preparation. Before use, the Carmustine powder for injection preparation is mixed with water for injection to form Carmustine liposome injection preparation. The injection preparation has Carmustine coated in double-layer liposome film of phospholipid and sterol and thus less toxic side effect of Carmustine to human body, so that it may be used continuously for raised cancer treating effect.

The invention discloses a vecuronium bromide liposome injection and a preparation method thereof. The liposome injection is prepared from vecuronium bromide, cholesterol, phosphatidyl ethanolamine, soyabean lecithin, twain 80, trehalose, mannitol and polyvinylpyrrolidone in a specific weight ratio. The liposome injection has high preparation stability, and the liposome is not cracked due to fusion, ice crystals and the like in the refrigerating process and keeps high entrapment efficiency even after being stored for a long-time. Due to the adoption of the injection, the solubility of the vecuronium bromide is improved, the quality of a preparation product is improved, toxic and side effects are reduced, the retention time of a medicament is increased during systemic circulation, the bioavailability of the medicament is enhanced, the curative effect is improved remarkably; and moreover, the preparation method is simple and is suitable for industrial production.

The invention discloses a sorafenib lipidosome freeze-dried injection for injection and a preparation method thereof. The freeze-dried injection is prepared from the following components in molar ratio: 1 mol of sorafenib, 5-60 mol of phospholipid, 1-30 mol of cholesterol, 1-60 mol of phosphatidyl glycerol, 1-10 mol of a polyethylene glycol surfactant and 50-400 mol of a freeze-drying protecting agent. The preparation method comprises the following steps: sequentially dissolving phospholipid, cholesterol, phosphatidyl glycerol, polyethylene glycol surfactant and sorafenib in an organic solvent in proportion; then, carrying out rotary and vacuum evaporation on the obtained organic solution in a round bottom glass bottle, so that a uniform thin film is formed on the inner wall of the glass bottle; then, adding a buffer liquid with the pH of 7-10 into the glass bottle to be continuously stirred to form a suspension; reducing the grain size of the suspension by an ultrasonic or high-pressure homogenizing method; and adding the freeze-drying protecting agent and freeze-drying. The sorafenib lipidosome disclosed by the invention remarkably improves the bioavailability and is stable in property, and the encapsulation efficiency can reach over 96%.

The invention discloses a thymalfasin liposome preparation for injecting and a preparation method thereof. The thymalfasin liposome preparation for injecting is prepared from thymalfasin, cholesterol, egg yolk lecithin, phosphatidyl inositol, sucrose ester and a pharmaceutically-acceptable carrier in a specific weight ratio, wherein the carrier is preferably mannitol and fucose. A liposome injection disclosed by the invention has high preparation stability, a liposome is prevented from cracking due to fusion, ice crystals and the like in a cooling process, and the liposome still keeps high packing rate and high stability after long-time storage. Due to the adoption of the thymalfasin liposome preparation, the solubility of thymalfasin is increased, the quality of a preparation product is improved, toxic and side effects are reduced, the retaining time of a medicament in body circulation is prolonged, the bioavailability of the medicament is increased, and a curative effect is increased remarkably; and moreover, the preparation method is simple, and is suitable for industrial production.

The invention provides a tropisetron hydrochloride liposome injection. The tropisetron hydrochloride liposome injection is mainly prepared from tropisetron hydrochloride, glycocholatesodium, cholesterol, gelatin, antioxygen and additive. The liposome injection improves the quality of preparation products, reduces toxic and side effects, improves bioavailability, and is high in preparation stability; and liposome is not broken due to dehydration, fusion, crystallization and the like during freeze-drying, and the liposome still keeps a good entrapment rate after the liposome is subjected to hydration and dissolution.

The invention provides an amoxicillin sodium flucloxacillin sodium medicine compound liposome injection which comprises amoxicillin sodium, flucloxacillin sodium, liposome carrier, lyoprotectant and optionally existing preservative, wherein the liposome carrier is soy lecithin and cholesterol. The liposome injection has good preparation stability, the liposome during freeze drying process does not crack caused by dehydration, fusion, ice crystal formation and the like; and likewise, the liposome keeps good encapsulation efficiency after hydration redissolution.

The invention discloses a monosialotetrahexosyl ganglioside sodium liposome injection and its preparation method. The liposome injection is made from monosialotetrahexosyl ganglioside sodium, hydrogenated egg yolk lecithin, soybean derived sterol, sodium deoxycholate, poloxamer 188, sodium bisulfite and other auxiliary materials. The liposome injection provided by the invention has good stability; the liposome will not break due to fusion and ice crystals during the freezing process and will also maintain good entrapment rate after stored for a long time. According to the invention, the quality of the preparation product is improved, toxic and side effects are minimized, retention time of the medicament in systematic circulation is increased, bioavailability and blood-brain barrier permeability of the medicament are raised and the curative effect is obviously enhanced. In addition, the preparation method is simple and is suitable for industrial production.

The invention discloses an ambroxol hydrochloride liposome injection and a preparation method thereof. The liposome injection is prepared from ambroxol hydrochloride, cholesterol, soybean phosphatidylserine, sojasterol, Tween 80, trehalose and PVP (Polyvinylpyrolidone) in a specific weight ratio. The liposome injection has high preparation stability, and a liposome does not crack due to fusion, ice crystals and the like and keeps high entrapment rate simultaneously after being stored for a long time; the solubility of the ambroxol hydrochloride is increased, the quality of a preparation product is enhanced, the toxic and side effects are reduced, the retention time of a medicament in systemic circulation is increased, the bioavailability of the medicament is enhanced, and the curative effect is enhanced remarkably; and moreover, a preparation method is simple, and is suitable for industrial mass production.

The invention discloses a calcium heparin liposome preparation for injection and a preparation method thereof. The liposome injection is made from the following components in a specific weight ratio: calcium heparin, cholesterol, phosphatidyl glycerol, lecithin, polyoxyethylene (40) hydrogenated castor oil, trehalose, sorbitol and polyvinylpyrrolidone. The liposome injection has good stability; the liposomes are not liable to be dehydrated, fused, crystallized or broken during the freezing process; and the liposomes maintain good encapsulation efficiency and stability after long-term storage.The solubility of calcium heparin is increased, the quality of the product is improved, the toxic and adverse effects are reduced, the retention time of drugs in the systemic circulation is increased, the bioavailability of drugs is improved, and the efficacy is greatly improved. Besides, the preparation method is simple and suitable for industrial production.